Metabolic Dysfunction-Associated Steatohepatitis: Is there evidence for fractured CD4+ T cell tolerance in the immunopathogenesis of MASH?

Authors

Abigail E Russi, Brian J DeBosch

Published in

Cellular and molecular gastroenterology and hepatology. Pages 101899. Sep 19, 2026. Epub Sep 19, 2026.

Abstract

Metabolic dysfunction-associated liver disease (MASLD) is defined by hepatic steatosis with concomitant metabolic risk factors and is the leading cause of chronic liver disease. In approximately one-third of individuals, the disease progresses to metabolic dysfunction-associated steatohepatitis (MASH), a more severe form encompassing steatosis with inflammation and hepatocellular injury predisposing to liver failure, cirrhosis, and hepatocellular carcinoma. The mechanism(s) responsible for this aberrant inflammation are unknown. In this review, we explore the breakdown of the hepatic tolerogenic environment in MASH with discussion on fractured CD4+ T cell tolerance as an integral driver of the progression of MASLD to MASH.

PMID:
42762950
Bibliographic data and abstract were imported from PubMed on 20 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.